Novo Nordisk Receives FDA Warning Over Ozempic Side Effect Reporting

Novo Nordisk has been issued a warning letter by the U.S. Food and Drug Administration (FDA) for failing to report all suspected side effects associated with its popular drug, Ozempic. Bloomberg posted on X, highlighting the FDA's concerns regarding the company's reporting practices. The warning underscores the importance of comprehensive monitoring and reporting of adverse effects in pharmaceutical products. Ozempic, widely used for managing type 2 diabetes, has gained significant attention for its effectiveness. However, the FDA's letter indicates that Novo Nordisk did not fully comply with regulatory requirements, potentially impacting patient safety. The company is expected to address these issues promptly to ensure compliance and maintain trust in its products.